SGLT2 Inhibitors in Diabetic Patients With Cardiovascular Disease or at High Cardiovascular Risk: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

ABSTRACT:

Objective

To investigate the effect of sodium-glucose cotransporter-2 inhibitors (SGLT2i) in patients with diabetes with cardiovascular disease (CVD) or at high cardiovascular risk.

Design

Systematic review and meta-analysis of randomized controlled trials (RCTs).

Data sources

Pubmed, Embase, the Cochrane Library, and ClinicalTrial.gov from their inception to August 28, 2021.

Review methods

Randomized control trials (RCTs) assess the effects of SGLT2i in patients with diabetes with cardiovascular disease or at high cardiovascular risk. Primary outcomes included the composite outcome of cardiovascular death (CV death) and hospitalization for heart failure (HHF), HHF, and renal composite outcomes. Secondary outcomes included major adverse cardiovascular events (M

SUBMITTER: Zhao Z 

PROVIDER: S-EPMC9087280 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature